2003 Fiscal Year Annual Research Report

再燃前立腺癌に対するペプチドワクチンの基礎及び臨床研究

Research Project

Project/Area Number	15591721
Research Institution	Kurume University
Principal Investigator	野口正典久留米大学, 医学部, 助教授 (10140691)
Research Abstract	再燃前立腺癌に対するペプチドワクチン療法は、第I相臨床試験においてその安全性が確認され,さらに数例においてはPSAの低下、骨転移の消失が認められた(Prostate 57:80-92,2003,Cancer Sci 95:77-84,2004)。また低容量エストラムスチン併用で臨床効果が増すことや、低容量でのエストラムスチン併用ではペプチドワクチン療法による免疫反応を抑制しないことが判明した(Prostate, in press)。2003年は従来のペプチドに前立腺特異抗原であるPSA, PAP由来の新規ペプチド(PSA152,PSA248,PAP213,PSMA624)を加え、再燃前立腺癌に対してテーラーメイド型ペプチドワクチン療法の早期第II相臨床試験を開始した。新規ペプチドを追加することにより従来のペプチドでの治療より良好な臨床効果を得ている。また、生存率においても新規ペプチドを追加することで予後の改善をみている(2004年欧州泌尿器科学会発表、論文投稿中)。これらの結果をもとに、ホルモン不応性再燃前立腺癌に対して臨床効果20%以上、2年以上の中央生存期間を目指して新規ペプチドを追加したテーラーメイド型ペプチドワクチンと低容量エストラムスチン併用療法のプロトコールによる後期第II相臨床試験への準備を進めている。このプロトコールではペプチド抗体でスクリーニングを行う予定である。これまでの検討でペプチド抗体でのワクチン選択はCTL測定での選択に優ることを確認している。抗体測定は安価、短時間測定ができ、高速自動化、大量サンプルの処理が可能となり、テーラーメイドワクチンの大規模臨床試験に用いることができ医薬品化における重要な因子になると思われる。

Research Products

(12 results)

All Other

All Publications (12 results)

[Publications] Noguchi M: "Percentage of the positive area of bone metastasis is an independent predictor of the disease death in advanced prostate cancer."Br J Cancer. 88. 195-201 (2003)
[Publications] Noguchi M: "Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer."Urology. 61. 993-998 (2003)
[Publications] Noguchi M: "Induction Of Cellular And Humoral Immune Responses To Tumor Cells And Peptides In HLA-A24 Positive Hormone-Refractory Prostate Cancer Patients By Peptide Vaccination."Prostate. 57. 80-92 (2003)
[Publications] Yahara J: "Quantitative evaluation of bone metastases in prostatic cancer patients during systemic treatment."BJU Int. 92. 379-384 (2003)
[Publications] Harada M: "Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24^+ prostate cancer patients."Prostate. 57. 152-159 (2003)
[Publications] Noguchi M: "Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens : lack of significance of secondary cancers."J Urol. 170. 459-463 (2003)
[Publications] Kobayashi K: "Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24^+ prostate cancer patients."Cancer Sci. 94. 622-627 (2003)
[Publications] Tanaka S: "Peptide vaccination for patients with melanoma and other types of cancers based on pre-existing peptide-specific cytotoxic T lymphocyte precursors in periphery."J Immunother. 26. 357-366 (2003)
[Publications] Noguchi M: "Chemohormonal Therapy As Primary Treatment For Metastatic Prostate Cancer : A Randomized Study Of Estramustine Phosphate Plus LHRH Agonist Versus Flutamide Plus LHRH Agonist."Int J Urol. 11. 103-109 (2004)
[Publications] Noguchi M: "Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer."Cancer Sci. 95. 77-84 (2004)
[Publications] Noguchi M: "Immunological Monitoring during Combination of Patient-Oriented Peptide Vaccination and Estramustine Phosphate in Patients with Metastatic Hormone Refractory Prostate Cancer."Prostate. 60. 32-45 (2004)
[Publications] Matsueda S: "Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2^+ patients with hormone-refractory prostate cancer."Cancer Immunol Immun. 53. 479-489 (2004)

2003 Fiscal Year Annual Research Report

再燃前立腺癌に対するペプチドワクチンの基礎及び臨床研究

Principal Investigator

野口 正典 久留米大学, 医学部, 助教授 (10140691)

Research Products

[Publications] Noguchi M: "Percentage of the positive area of bone metastasis is an independent predictor of the disease death in advanced prostate cancer."Br J Cancer. 88. 195-201 (2003)

[Publications] Noguchi M: "Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer."Urology. 61. 993-998 (2003)

[Publications] Noguchi M: "Induction Of Cellular And Humoral Immune Responses To Tumor Cells And Peptides In HLA-A24 Positive Hormone-Refractory Prostate Cancer Patients By Peptide Vaccination."Prostate. 57. 80-92 (2003)

[Publications] Yahara J: "Quantitative evaluation of bone metastases in prostatic cancer patients during systemic treatment."BJU Int. 92. 379-384 (2003)

[Publications] Harada M: "Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24^+ prostate cancer patients."Prostate. 57. 152-159 (2003)

[Publications] Noguchi M: "Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens : lack of significance of secondary cancers."J Urol. 170. 459-463 (2003)

[Publications] Kobayashi K: "Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24^+ prostate cancer patients."Cancer Sci. 94. 622-627 (2003)

[Publications] Tanaka S: "Peptide vaccination for patients with melanoma and other types of cancers based on pre-existing peptide-specific cytotoxic T lymphocyte precursors in periphery."J Immunother. 26. 357-366 (2003)

[Publications] Noguchi M: "Chemohormonal Therapy As Primary Treatment For Metastatic Prostate Cancer : A Randomized Study Of Estramustine Phosphate Plus LHRH Agonist Versus Flutamide Plus LHRH Agonist."Int J Urol. 11. 103-109 (2004)

[Publications] Noguchi M: "Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer."Cancer Sci. 95. 77-84 (2004)

[Publications] Noguchi M: "Immunological Monitoring during Combination of Patient-Oriented Peptide Vaccination and Estramustine Phosphate in Patients with Metastatic Hormone Refractory Prostate Cancer."Prostate. 60. 32-45 (2004)

[Publications] Matsueda S: "Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2^+ patients with hormone-refractory prostate cancer."Cancer Immunol Immun. 53. 479-489 (2004)

野口正典久留米大学, 医学部, 助教授 (10140691)